XX Rexxys Xxborxxorixx Inxx Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: XX Rexxys Xxborxxorixx Inxx Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

XX Rexxys Xxborxxorixx Inxx — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

XX Rexxys Xxborxxorixx Inxx

Pharmaceutical Importer · United States · Diabetes & Endocrine Focus · $200.0K Total Trade · DGFT Verified

XX Rexxys Xxborxxorixx Inxx is a pharmaceutical importer based in United States with a total trade value of $200.0K across 2 products in 2 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. XX Rexxys Xxborxxorixx Inxx sources from 1 verified Indian supplier, with Dr Reddy S Laboratories Limited accounting for 100.0% of imports.

XX Rexxys Xxborxxorixx Inxx — Import Portfolio & Supplier Network

XX Rexxys Xxborxxorixx Inxx import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to XX Rexxys Xxborxxorixx Inxx?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr Reddy S Laboratories Limited	$2.8M	65	100.0%

XX Rexxys Xxborxxorixx Inxx sources from 1 verified Indian supplier across 26 distinct formulations. The sourcing is highly concentrated — Dr Reddy S Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Atorvastatcaltabusp20mg(cryst	$321.2K	8
Atorvastatcaltabusp40mg(cryst	$294.8K	6
Tizanidine tablets USP 4 MG	$216.9K	6
Atorvastatcaltabusp80mg(cryst)	$200.0K	4
Fexofenadine hydrochloride tablets	$150.0K	3
Atorvastatcaltabusp80mg(cryst) 500s	$150.0K	3
Lurasidone hcl TAB 80MG 30s hdpe	$150.0K	3
Tadalafil tablets USP 5MG 30s hdpe	$100.0K	2
Tadalafil tablets USP 10MG 30s hdpe	$100.0K	2
Atorvastatcaltabusp20mg(cryst) 500s	$100.0K	2
Tizanidine tablets USP 4 MG	$100.0K	2
Vigabatrin tablets USP 500MG 100's	$100.0K	2
Glimepiride tablets 4MG (500's Pack)	$100.0K	2
Tizanidine tablets USP 4 MG (150's	$100.0K	2
Posaconazole delayed release tablets	$100.0K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glimepiride	Diabetes & Endocrine	$100.0K	2	0.1%	9
2	Posaconazole	Advanced Antifungals	$100.0K	2	0.1%	7

XX Rexxys Xxborxxorixx Inxx imports 2 pharmaceutical products across 2 categories into United States totaling $200.0K.

XX Rexxys Xxborxxorixx Inxx — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

XX Rexxys Xxborxxorixx Inxx is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations. The company operates as a wholesaler, sourcing medications from international suppliers to distribute within the U.S. market. While specific details about its headquarters and parent company are not publicly disclosed, XX Rexxys Xxborxxorixx Inxx plays a significant role in the U.S. pharmaceutical distribution network by facilitating the importation and distribution of essential medications.

2Distribution Network

The distribution network of XX Rexxys Xxborxxorixx Inxx encompasses multiple warehouse locations across the United States, strategically positioned to ensure efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling nationwide coverage and prompt fulfillment of orders. While specific details about international distribution are not available, XX Rexxys Xxborxxorixx Inxx's operations are primarily focused on the U.S. market, ensuring a reliable supply chain for domestic healthcare providers.

3Industry Role

In the U.S. pharmaceutical supply chain, XX Rexxys Xxborxxorixx Inxx functions as a primary wholesaler. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various healthcare providers, including hospitals, clinics, and pharmacies. By sourcing medications globally, XX Rexxys Xxborxxorixx Inxx contributes to the diversification and availability of pharmaceutical products within the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — XX Rexxys Xxborxxorixx Inxx

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

XX Rexxys Xxborxxorixx Inxx exhibits a high degree of supplier concentration, with all its pharmaceutical imports originating from a single supplier: Dr. Reddy's Laboratories Limited. This single-source dependency indicates a strategic choice to maintain a focused and potentially more manageable supply chain. The stability of this relationship is evidenced by the consistent volume of shipments—65 shipments totaling $2.8 million—suggesting a strong and reliable partnership. However, such concentration also poses risks; any disruptions at Dr. Reddy's Laboratories Limited could significantly impact XX Rexxys Xxborxxorixx Inxx's ability to meet market demand.

2Supply Chain Resilience

The resilience of XX Rexxys Xxborxxorixx Inxx's supply chain is closely tied to the operations of Dr. Reddy's Laboratories Limited. The company's reliance on a single supplier for all its imported pharmaceutical formulations means that any disruptions—such as production delays, regulatory issues, or logistical challenges—at Dr. Reddy's could directly affect XX Rexxys Xxborxxorixx Inxx's ability to supply products to the U.S. market. While Dr. Reddy's Laboratories Limited is a reputable and established supplier, XX Rexxys Xxborxxorixx Inxx may consider diversifying its supplier base to enhance supply chain resilience and mitigate potential risks.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations that ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name counterpart.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include obtaining an FDA registration for the foreign manufacturer and ensuring that the imported drugs comply with the FDA's Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from other regulatory bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), provided they meet the FDA's criteria. Additionally, wholesale distributors must obtain state-specific licenses to operate legally within each jurisdiction.

Quality & Labeling

XX Rexxys Xxborxxorixx Inxx — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

XX Rexxys Xxborxxorixx Inxx's focus on importing pharmaceutical formulations in the therapeutic areas of Diabetes & Endocrine and Advanced Antifungals indicates a strategic alignment with prevalent health concerns in the U.S. market. The high import values for Glimepiride and Posaconazole suggest significant market demand for these medications. This focus allows XX Rexxys Xxborxxorixx Inxx to cater to specific patient needs, positioning itself as a key supplier in these therapeutic categories.

2Sourcing Profile

XX Rexxys Xxborxxorixx Inxx's sourcing strategy is centered on importing generic drug formulations from India, particularly in the therapeutic areas of Diabetes & Endocrine and Advanced Antifungals. The company's reliance on Dr. Reddy's Laboratories Limited for all its imports indicates a preference for established suppliers with a proven track record in quality and regulatory compliance. This approach ensures a consistent supply of high-quality medications to meet the needs of the U.S. market.

3Market Positioning

Based on its product mix, XX Rexxys Xxborxxorixx Inxx serves the U.S. market segment that includes retail pharmacies, hospitals, and clinics. By importing essential medications in high-demand therapeutic areas, the company positions itself as a critical supplier, ensuring that healthcare providers have access to necessary treatments for their patients.

Seller's Guide — How to Become a Supplier to XX Rexxys Xxborxxorixx Inxx

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with XX Rexxys Xxborxxorixx Inxx, particularly if they can offer complementary products or demonstrate the ability to meet the FDA's quality and regulatory standards. Diversifying the supplier base could enhance XX Rexxys Xxborxxorixx Inxx's supply chain resilience and reduce dependency on a single source. Potential gaps in the current sourcing include the need for additional formulations in other therapeutic areas to meet broader market demands.

2Requirements & Qualifications

Indian exporters seeking to supply XX Rexxys Xxborxxorixx Inxx and the U.S. market must obtain FDA registration for their manufacturing facilities and ensure compliance with the FDA's GMP standards. Possessing GMP certifications recognized by the FDA, such as those from the EMA or WHO, can facilitate the approval process. Additionally, exporters must adhere to U.S. labeling requirements and serialization mandates to ensure product acceptance and marketability.

3How to Approach

Frequently Asked Questions — XX Rexxys Xxborxxorixx Inxx

What products does XX Rexxys Xxborxxorixx Inxx import from India?

XX Rexxys Xxborxxorixx Inxx imports 2 pharmaceutical products across 2 categories. Top imports: Glimepiride ($100.0K), Posaconazole ($100.0K).

Who supplies pharmaceuticals to XX Rexxys Xxborxxorixx Inxx from India?

XX Rexxys Xxborxxorixx Inxx sources from 1 verified Indian suppliers. The primary supplier is Dr Reddy S Laboratories Limited (100.0% of imports, $2.8M).

What is XX Rexxys Xxborxxorixx Inxx's total pharmaceutical import value?

XX Rexxys Xxborxxorixx Inxx's total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does XX Rexxys Xxborxxorixx Inxx focus on?

XX Rexxys Xxborxxorixx Inxx imports across 2 categories. The largest: Diabetes & Endocrine (50.0%), Advanced Antifungals (50.0%).

Get Full XX Rexxys Xxborxxorixx Inxx Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.